Daniel Jacoby, MD

Printed as of 11/19/2026

Disclosures

Personal Commercial (7)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Abbott	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
alnylam	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Cytokinetics	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Myokardia	Other - *EXPLORER STEERING COMMITTEE*	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Pfizer Inc	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Propria LLC	Other - *Patent/IP*	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Spouse/Domestic Partner/Immediate Household Member			
Propria	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
NHLBI	Data Safety Monitoring Board	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*

Clinical Trial Enroller (9)

Trial Name	Trial Sponsor	Trial Funding Source
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation	Abbott Vascular	
VALOR HCM	BMS	BMS
PARACHUTE IV – Percutaneous ventricular restoration in chronic heart failure due to ischemic heart disease	Cardiokinetics	
EIDOS- AG10	Eidos	
MAVERICK	MYOCARDIA	
EXPLORER	MyoKardia	
PIONEER	MyoKardia	
Transthyretin-associated amyloidosis outcomes survey (THAOS)	Pfizer	
MOMENTUM 3	Thoratec	

Institutional Financial Decision-Making Role (1)

Funding Source	Institutional Compensation Level
YNHH	Significant (>= $5,000)

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 4/30/2021

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 4/30/2021
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 4/30/2021
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 5/26/2021

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.